Satisfaction and compliance in hormonal contraception: The result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy

被引：7

作者：

Crosignani P.G. ^{[1
]}

Nappi C. ^{[2
,19
]}

Ronsini S. ^{[3
,23
]}

Bruni V. ^{[4
,10
]}

Marelli S. ^{[4
]}

Sonnino D. ^{[5
]}

Affronti G. ^{[6
]}

Benagiano G. ^{[7
]}

Benedetto C. ^{[8
]}

Bolis G. ^{[9
]}

Cianci A. ^{[11
]}

Fedele L. ^{[12
]}

Garsia A. ^{[13
]}

Genazzani A.R. ^{[14
]}

Gherzi R. ^{[15
]}

Masellis G. ^{[16
]}

Melis G. ^{[17
]}

Moscarini M. ^{[18
]}

Piccione E. ^{[20
]}

Quartararo P. ^{[21
]}

Ragni N. ^{[22
]}

Scagliola P. ^{[24
]}

Schönauer S. ^{[25
]}

Sismondi P. ^{[26
]}

Venturini P.L. ^{[27
]}

Volpe A. ^{[28
]}

Zullo F. ^{[29
]}

机构：

[1] II Institute of Obstetrics and Gynaecology, University of Milan, Milan

[2] Department of Obstetric-Gynaecological, Urological Sciences and Reproduction Medicine, University of Naples, Naples

[3] Department of Maternal and Children's Sciences, ASL SA 3 San Luca Hospital, Vallo della Lucania, SA

[4] Department of Gynaecology, Perinatology and Human Reproduction, University of Florence, Florence

[5] Medical Affairs Department, Janssen-Cilag SpA, Cologno Monzese, MI

[6] Azienda Ospedaliera di Perugia, Perugia

[7] Università degli Studi di Roma La Sapienza, Roma

[8] Azienda Ospedaliera O.I.R.M.S. Anna, Torino

[9] Azienda Ospedaliera S. Paolo, Milano

[10] Policnico Careggi, Università degli Studi di Firenze, Firenze

[11] Azienda Ospedaliera Universitaria V. Emanuele-Ferrarotto-S. Bambino, Catania

[12] Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano

[13] Azienda Ospedaliera Niguarda Cà Granda, Milano

[14] Università degli Studi di Pisa, Pisa

[15] Azienda Ospedaliera Maggiore della Carità, Novara

[16] Ospedale Civile Ramazzini, Carpi, MO

[17] Ospedale S. Giovanni di Dio, Cagliari

[18] Azienda Ospedaliera S. Andrea, Roma

[19] Università degli Studi Federico II, Napoli

[20] Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma

[21] Policlinico Paolo Giaccone, Palermo

[22] Università degli Studi di Genova, Genova

[23] Ospedale San Luca, Vallo della Lucania, SA

[24] Spedali Civili di Brescia, Brescia

[25] Azienda Ospedaliera Ospedale Policlinico Consorziale, Bari

[26] Azienda Sanitaria Ospedaliera Ordine Mauriziano, Torino

[27] Istituto Giannini Gaslini, Genova

[28] Azienda Ospedaliera di Modena, Modena

[29] Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro

来源：

BMC Women's Health | / 9卷 / 1期

关键词：

Oral Contraceptive; Contraceptive Method; Unintended Pregnancy; Ethinylestradiol; Bioelectrical Impedance Analysis;

D O I：

10.1186/1472-6874-9-18

中图分类号：

学科分类号：

摘要：

Background: For many women finding the right contraceptive method can be challenging and consistent and correct use over a lifetime is difficult. Even remembering to take a birth control pill every day can be a challenge. The primary objective of this study was to evaluate women's experience with a weekly ethinylestradiol/norelgestromin contraceptive patch (EE/NGMN patch), given new technologies recently developed in hormonal contraception to increase women's options in avoiding daily dosing. Methods: In 24 Italian sites, 207 women received the EE/NGMN patch for up to 6 cycles. At study end, overall satisfaction and preference, as well as compliance, efficacy and safety, were evaluated. Results: 175 women (84.5%) completed the study. The overall satisfaction rate was 88%; convenience and once-a-week frequency of the patch were especially appreciated. At baseline, 82 women (39.4%) were using a contraceptive method, mainly oral contraceptives and barrier methods, but only 45.1% were very satisfied/satisfied; after 6 months with the patch, 86.3% of this subset was very satisfied/satisfied. Considering the method used in the 3 months before the study entry, 78.1% strongly preferred/preferred the patch, for convenience (53.9%), ease of use/ simplicity (28.9%), fewer (9.2%) and less severe (2.6%) side effects. Compliance was very high: 1034/1110 cycles (93.2%) were completed with perfect compliance and the mean subject's compliance score was 90%. One on-therapy pregnancy occurred. The patch was safe and well tolerated: adverse events frequency was low, with predominantly single reports of each event. Most of them started and subsided during cycle 1. Conclusion: This study demonstrated that the EE/NGMN patch is associated with high satisfaction levels and excellent compliance. At study end, the majority of women indicated that they would continue using the patch. © 2009 Crosignani et al; licensee BioMed Central Ltd.

引用

共 37 条

[11]

Schindler A.E., Campagnoli C., Druckmann R., Huber J., Pasqualini J.R., Schweppe K.W., Thijssen J.H., Classification and pharmacology of progestins, Maturitas, 46, SUPPL. 1, (2003)

[12]

Phillips A., Hahn D.W., McGuire J.L., Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity, Am J Obstet Gynecol, 167, 4 PART 2, pp. 1191-1196, (1992)

[13]

White T., Jain J.K., Stanczyk F.Z., Effect of oral versus transdermal steroidal contraceptives on androgenic markers, Am J Obstet Gynecol, 192, 6, pp. 2055-2059, (2005)

[14]

Rabe T., Kowald A., Ortmann J., Rehberger-Schneider S., Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro, Gynecol Endocrinol, 14, 4, pp. 223-230, (2000)

[15]

Paris F., Rabeolina F., Balaguer P., Bacquet A., Sultan C., Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line, Gynecol Endocrinol, 23, 4, pp. 193-197, (2007)

[16]

Smallwood G.H., Meador M.L., Lenihan Jr. J.P., Shangold G.A., Fisher A.C., Creasy G.W., Efficacy and safety of a transdermal contraceptive system, Obstet Gynecol, 98, 5 PART 1, pp. 799-805, (2001)

[17]

Audet M.C., Moreau M., Koltun W.D., Waldbaum A.S., Shangold G.A., Fisher A.C., Creasy G.W., Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: A randomized controlled trial, JAMA, 285, 18, pp. 2347-2354, (2001)

[18]

Zieman M., Guillebaud J., Weisberg E., Shangold G.A., Fisher A.C., Creasy G.W., Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: The analysis of pooled data, Fertil Steril, 77, 2 SUPPL. 2, (2002)

[19]

Pierson R.A., Archer D.F., Moreau M., Shangold G.A., Fisher A.C., Creasy G.W., Ortho Evra/Evra versus oral contraceptives: Follicular development and ovulation in normal cycles and after an intentional dosing error, Fertil Steril, 80, 1, pp. 34-42, (2003)

[20]

Archer D.F., Bigrigg A., Smallwood G.H., Shangold G.A., Creasy G.W., Fisher A.C., Assessment of compliance with a weekly contraceptive patch (Ortho Evra/ Evra) among North American women, Fertil Steril, 77, 2 SUPPL. 2, (2002)

← 1 2 3 4 →